Virpax Pharmaceuticals provides update on Envelta development program

Virpax Pharmaceuticals announced recent progress made in its Envelta development program. Envelta is the company’s non-opioid pain product candidate for acute and chronic pain that is being funded under an in-kind grant from the National Center for Advancing Translational Sciences, or NCATS, part of the National Institutes of Health, or NIH. Dose ranging studies for Envelta in both rats and dogs were recently completed, and the intranasal administration of Envelta was well-tolerated and no adverse effects were observed. The data from these studies will be used in Virpax’s Investigational New Drug, or IND, application to the FDA as well as to establish safe dosing for the first-in-human trials of Envelta.